Harpoon Therapeutics
South San Francisco, US · Delaware corporation · 3 known investors
Founders & leadership
LN
Luke Nathaniel WalkerExecutive
JE
Julie EastlandExecutive
Board
RH
Ronald HuntBoard director
MC
Mark ChinBoard director
AC
Alan ColowickBoard director
JD
Jonathan DrachmanBoard director
JV
Joanne VineyBoard director
JB
Joseph BailesBoard director
AR
Andrew RobbinsBoard director
SM
Scott MyersBoard director
LP
Lauren P. SilvernailBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$220.3M disclosed across 4 rounds · 2017–2023
▶$100.2MraisedOct 2023 · 18 investors · BiotechnologyRule 506(b)
▶$100.2MraisedOct 2023 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew RobbinsDirector
- Julie EastlandExecutive Officer, Director
- Luke WalkerExecutive Officer
- Mark ChinDirector
- Scott MyersDirector
- Jonathan DrachmanDirector
- Ronald HuntDirector
- Joseph BailesDirector
- Lauren SilvernailDirector
- Offering amount
- $100.2M
- Amount sold
- $100.2M
- Sales commissions
- $6.4M
- Placement agents
- Cowen and Company, LLC, H.C. Wainwright & Co., LLC, Canaccord Genuity LLC
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedApr 2023 · 6 investors · BiotechnologyRule 506(b)
▶$25MraisedApr 2023 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan DrachmanDirector
- Joanne VineyDirector
- Joseph BailesDirector
- Ronald HuntDirector
- Andrew RobbinsDirector
- Mark ChinDirector
- Luke Nathaniel WalkerExecutive Officer
- Julie EastlandExecutive Officer, Director
- Scott MyersDirector
- Lauren P. SilvernailDirector
- Alan ColowickDirector
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$70MraisedNov 2018 · 17 investors · BiotechnologyRule 506(b)
▶$70MraisedNov 2018 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan DrachmanDirector
- Natalie R. SacksExecutive Officer
- Julie EastlandDirector
- Patrick BaeuerleDirector
- Mark ChinDirector
- Holger WescheExecutive Officer
- Gerald McMahonExecutive Officer, Director
- Scott MyersDirector
- Ron HuntDirector
- Georgia L. ErbezExecutive Officer
- Luke EvninDirector
- Offering amount
- $70M
- Amount sold
- $70M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$25.2MraisedJun 2017 · 7 investors · BiotechnologyRule 506(b)
▶$25.2MraisedJun 2017 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ron HuntDirector
- Mark ChinDirector
- Patrick BaeuerleDirector
- Gerald McMahonExecutive Officer, Director
- Luke EvninDirector
- Pablo CagnoniDirector
- William E. PichtExecutive Officer
- Dan HicklinDirector
- Offering amount
- $45.2M
- Amount sold
- $25.2M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Harpoon Therapeutics's investors?
- Harpoon Therapeutics's investors include K2 HealthVentures, Taiho Ventures, LLC, MPM BioImpact.
- How much funding has Harpoon Therapeutics raised?
- Harpoon Therapeutics has disclosed $220.3M raised across 4 rounds.
- Where is Harpoon Therapeutics headquartered?
- Harpoon Therapeutics is headquartered in South San Francisco, US.